Group 1 - The core viewpoint of the news is that Sichuan Huiyu Pharmaceutical Co., Ltd. reported a significant decline in its financial performance for Q1 2025, marking the first quarterly loss since its listing in 2021 [1] - In Q1 2025, the company achieved an operating income of 239 million yuan, a year-on-year decrease of 1.46% [1] - The net profit attributable to shareholders was a loss of 25.63 million yuan, a decline of 155.19% compared to a profit of 46.44 million yuan in Q1 2024 [1] Group 2 - The substantial decline in net profit and the occurrence of a loss were attributed to fluctuations in the stock price of Tongyuan Kang Pharmaceutical Co., Ltd., in which the company invested 100 million yuan in 2023 [1] - The company's Q1 2025 report indicated that the fair value changes and disposal gains/losses from financial assets and liabilities amounted to approximately -81.15 million yuan [1] - Huiyu Pharmaceutical was established in 2010 and focuses on the research, production, and sales of innovative drugs and high-quality generic drugs in the oncology field [2] Group 3 - The company has faced disciplinary actions; the former chairman and general manager Ding Zhao was criticized by the Shanghai Stock Exchange for stock trading activities involving his parents [2] - From November 2018 to the present, Ding Zhao has served as chairman and general manager, and his parents engaged in stock trading that violated regulations [2] - The trading activities included buying and selling approximately 142,200 shares of Huiyu Pharmaceutical, with total transaction amounts of about 2.81 million yuan for purchases and 2.53 million yuan for sales [2]